A Phase 1/2 interventional study of Tazemetostat and Abiraterone/prednisone in Metastatic Prostate Cancer and Metastatic Castration-resistant Prostate Cancer, sponsored by Epizyme, Inc.. Terminated at 24 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Epizyme, Inc. (part of Ipsen) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 40th largest by enrollment, is one of 7 that started in 2019, is one of 11 in phase 1/2, and was the 98th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Hyundai Bioscience Co., Ltd. · Sites in Korea, Republic of
Ages 19+ · Men only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 78 · Phase 3 18 · Phase 4 7
First in 2005; this study’s year is marked. 7 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 52 across the 125 interventional studies. Of the 81 that completed or were terminated, 49 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 125 have an industry lead sponsor. The 10 most frequent:
This study is registered under Epizyme, Inc., one of the names counted as Ipsen. Under that name alone:
Epizyme, Inc. is the lead sponsor of 21 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.
27 studies in Prostatic Neoplasms by Ipsen: 1 open now, 1 under way, none of them phase 3. Of 26 finished, 12 (46%) have results posted.
Among the 27 studies in Prostatic Neoplasms by Ipsen, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2019, is the only one in phase 1/2, and was the 22nd registered.
Ipsen’s Prostatic Neoplasms studies by the year they started, since 2006.
13 of the studies testing enzalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT05873192M.D. Anderson Cancer CenterPresurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | 2026-12-31 |
| NCT03344211University of Southern CaliforniaEnzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, from their registry updates:
Among Ipsen’s 27 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a global, multi-center, open-label, randomized phase 1b/2, active-controlled safety and efficacy study of oral administration of tazemetostat in combination with enzalutamide or abiraterone/prednisone (phase 1b) versus enzalutamide or abiraterone/prednisone alone in asymptomatic or mildly symptomatic subjects with progressive, metastatic castration-resistant prostate cancer (mCRPC) who have progressed on either abiraterone acetate, enzalutamide, or apalutamide or who are second generation anti-androgen treatment naive, and who have not received chemotherapy for mCRPC.
This study is designed to determine the recommended phase 2 doses (RP2D) of tazemetostat in combination with either enzalutamide or abiraterone/prednisone, based on safety, tolerability, pharmacokinetic, pharmacodynamic, and efficacy profiles.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Progressive disease in the setting of medical or surgical castration (ie, castration- resistant prostate cancer [CRPC]) by PCWG3 criteria for study entry.
prostate cancer disease, documented by the following imaging
Prior treatment with a second-generation androgen inhibitor as follows:
Exclusion Criteria:
Treatment with any of the following for prostate cancer within the indicated timeframe prior to day 1 of starting study treatment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Phase 1b, abiraterone/prednisone will be administered in combination with tazemetostat in cycle 1 (28 days) to establish the recommended dose of tazemetostat in this combination; participants may continue treatment in additional 28-day cycles, as tolerated, until progression or unacceptable toxicity
Drug: Tazemetostat · Drug: Abiraterone/prednisone
In Phase 1b, enzalutamide will be administered in combination with tazemetostat in cycle 1 (28 days) to establish the recommended dose of tazemetostat in this combination; participants may continue treatment in additional 28-day cycles, as tolerated, until progression or unacceptable toxicity
Drug: Tazemetostat · Drug: Enzalutamide
Participants will receive the newly established recommended phase 2 dose, orally twice daily when given in combination with enzalutamide) as determined in phase 1b part of the study) or enzalutamide alone. All participants will receive treatment in 28-day cycles.
Drug: Tazemetostat · Drug: Enzalutamide
In Phase 2, Enzalutamide will be administered on cycle 1 day 1
Drug: Enzalutamide
Tazemetostat (EPZ-6438) is a selective small-molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
Also known as: EPZ-6438, E7438, IPN60200
1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily in combination with prednisone 5 mg administered orally twice daily.
Also known as: Zytiga
enzalutamide 160 mg (four 40 mg capsules) orally once daily
Also known as: Xtandi
Phase 1b: Number of Participants With Treatment-Emergent Non-Serious Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product and which did not necessarily had a causal relationship with this study drug. An SAE was an AE which occurred during any study phase and at any dose of study drug, that fulfilled 1 or more of following: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital abnormality or birth defect, or was an important medical event that might jeopardize the participant or might require medical intervention to prevent one of the outcomes listed above. TEAEs were AEs that started or worsened in severity on or after the date of the first dose of study drug through 30 after the end of study drug, or prior to initiation of another investigational agent or cytotoxic chemotherapy. The treatment-emergent non-serious AEs are presented with a frequency threshold of 5%.
Time frame: From first dose of study drug (Day 1) up to either 30 days after last dose of study drug or until the initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 149 weeks
Phase 1b: Recommended Phase 2 Dose (RP2D) of Tazemetostat
RP2D was based on pharmacokinetics (PK) parameters, pharmacodynamics (PD) parameters as well as efficacy and the overall tolerability of each combination (tazemetost with enzalutamide or tazemetostat with abiraterone/prednisone).
Time frame: From Day 1 up to Day 28 of Cycle 1 (each cycle was 28 days)
Phase 2: Radiographic Progression-Free Survival (rPFS)
rPFS was defined as the time from date of randomization (phase 2)/date of first dose of study drug (phase 1b) to the first objective evidence of radiographic progression using response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) (soft tissue) and prostate cancer clinical trials working group 3 (PCWG3) (bone), or death from any cause, whichever occurred first. The radiographic PD for soft tissue lesion was determined based on computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria and no confirmatory scan was required for soft tissue PD; for bone lesion was determined by 2 or more new bone lesions on bone scan per PCWG3 criteria (i.e., the appearance of 2 or more new bone lesions on bone scan) and the 2 scans (i.e., the confirmatory scan is required for bone disease progression) should be at least 6 weeks apart from each other.
Time frame: Assessments performed at screening (within 4 weeks of randomization) and every 8 weeks for first 6 months and then every 12 weeks thereafter, until death, PD, unacceptable toxicity, consent withdrawal, or termination of study. Approximately 200 weeks
Phase 1b and 2: Percentage of Participants With Confirmed Prostate-Specific Antigen >=50% (PSA50) Response
Blood samples were collected for evaluation of PSA. Confirmed PSA50 response was defined as \>=50% decline of PSA from baseline at any time on study for participants with a baseline PSA \>=1.0 microgram per liter (mcg/L) (nanogram/milliliter \[ng/mL\]) per PCWG3 criteria. Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization.
Time frame: From Cycle 1 Day 1 (Baseline) up to either 30 days after last dose of study drug or until initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 149 weeks and 191 weeks for Phase 1b and Phase 2 respectively
Phase 1b and 2: Objective Response Rate (ORR)
ORR was defined as the percentage of participants with complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions, any pathological lymph nodes (LN) must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
Time frame: Tumor assessments performed at screening (within 4 weeks of randomization) and every 8 weeks for first 6 months and then every 12 weeks thereafter, until death, PD, unacceptable toxicity, consent withdrawal, or termination of study.Approximately 259 weeks
Phase 1b and 2: Best Overall Response (BOR)
BOR was defined as percentage of participants with CR, PR, stable disease (SD), PD, or not evaluable (NE). CR was defined as disappearance of all target lesions, any pathological LN must be \<10 mm in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the drug started. In addition, the sum had an absolute increase from nadir of 5 mm. NE was defined as which cannot be classified by 1 of the above preceding definitions. Percentages are rounded off to the tenth decimal place.
Time frame: Tumor assessments performed at screening (within 4 weeks of randomization) and every 8 weeks for first 6 months and then every 12 weeks thereafter, until death, PD, unacceptable toxicity, consent withdrawal, or termination of study.Approximately 259 weeks
Phase 1b and 2: Disease Control Rate (DCR) at 6 Months
DCR at 6 months (24 weeks) was defined as percentage of participants with measurable soft tissue disease at baseline who had BOR of CR or PR and remaining on study without progression at 23 weeks or with a duration of SD for at least 23 weeks after of randomization (phase 2)/first dose (phase 1b) using overall imaging-based response assessed by RECIST 1.1 (soft tissue) and PCWG-3 criteria (bone). BOR: percentage of participants with CR, PR, SD, PD, or NE. CR: disappearance of all target lesions, any pathological LN must be \<10 mm in the short axis. PR: at least a 30% decrease in sum of diameters of target lesions, taking as a reference, baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: at least a 20% increase in sum of diameters of target lesions, taking as a reference, smallest sum of diameters recorded since the drug started. In addition, sum had an absolute increase from nadir of 5 mm.
Time frame: Baseline and at 6 months (24 weeks)
Phase 1b and 2: Time to First Skeletal-Related Event (SRE) Per Prostate Cancer Clinical Trials Working Group 3 Criteria
Time to first SRE per PCWG3 criteria was defined as the time from the date of randomization (phase II)/date of the first dose of study drug (phase Ib) to the date of first SRE. An SRE was defined as radiation therapy or surgery to bone, pathologic bone fracture, or spinal cord compression.
Time frame: From first dose of study drug (Phase 1b) and randomization (Phase 2) (Day 1) up to approximately 259 weeks
Phase 1b and 2: Time to Initiation of the Next Systemic Treatment (TTNT) for Prostate Cancer
TTNT was defined as the time from the date of randomization (phase II)/date of the first dose of the study drug (phase Ib) to the date of the first documented administration of systemic treatment for prostate cancer.
Time frame: From first dose of study drug (Phase 1b) and randomization (Phase 2) (Day 1) up to approximately 259 weeks
Phase 1b and 2: Time to Prostate-Specific Antigen Progression (TTPP)
TTPP was defined as the duration from the date of randomization (phase II)/date of first dose of study drug (phase Ib) to the date of first PSA progression per PCWG3 criteria. PSA progression was defined as a \>=25% increase and an absolute increase of \>=2 mcg/L (2 ng/mL) above the nadir (or baseline value for participants who did not have a decline in PSA value beyond 12 weeks). Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization.
Time frame: From first dose of study drug (Phase 1b) and randomization (Phase 2) (Day 1) up to approximately 259 weeks
Phase 1b and 2: Percentage of Participants With Reduction in Circulating Tumor Cells (CTC)
Blood samples were collected for evaluation of CTC. Reduction in CTC was defined as participants from a state of having a detectable number of CTCs to having an undetectable number of CTCs. Percentage of participants with detectable CTC at baseline and non-detectable CTC are presented. Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization. Percentage of participants with detectable CTC at baseline and non-detectable CTC at any post-baseline time point up to 149 weeks and 191 weeks for Phase 1b and Phase 2 respectively are presented.
Time frame: From Cycle 1 Day 1 (Baseline) up to either 30 days after last dose of study drug or until initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 149 weeks and 191 weeks for Phase 1b and Phase 2 respectively
Phase 1b and 2: Percentage of Participants With Circulating Tumor Cells Response
Blood samples were collected for evaluation of CTC. CTC response was defined as a \>=30% reduction in CTC number from baseline in participants who entered the study. Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization.
Time frame: From Cycle 1 Day 1 (Baseline) up to either 30 days after last dose of study drug or until initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 149 weeks and 191 weeks for Phase 1b and Phase 2 respectively
Phase 2: Number of Participants With Treatment-Emergent Non-Serious Adverse Events and Treatment-Emergent Serious Adverse Events
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product and which did not necessarily had a causal relationship with this study drug. An SAE was an AE which occurred during any study phase and at any dose of the study drug, that fulfilled 1 or more of following: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital abnormality or birth defect, or was an important medical event that might jeopardize the participant or might require medical intervention to prevent one of the outcomes listed above. TEAEs were AEs that started or worsened in severity on or after the date of the first dose of study drug through 30 after end of study drug, or prior to initiation of another investigational agent or cytotoxic chemotherapy. The treatment-emergent non-serious AEs are presented with a frequency threshold of 5%.
Time frame: From first dose of study drug (Day 1) up to either 30 days after last dose of study drug or until the initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 191 weeks
Phase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Tazemetostat
Blood samples were collected at specified timepoints for the assessment of AUC0-last of tazemetostat.
Time frame: Cycle 1 Days 2 and 21 (each cycle was 28 days)
Phase 1b: Maximum Plasma Concentration (Cmax) of Tazemetostat
Blood samples were collected at specified timepoints for the assessment of Cmax of tazemetostat.
Time frame: Cycle 1 Days 2 and 21 (each cycle was 28 days)
Phase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 8 Hours Post-Dose (AUC0-8) of Tazemetostat
Blood samples were collected at specified timepoints for the assessment of AUC0-8 of tazemetostat.
Time frame: Up to 8 hours post-dose on Cycle 1 Days 2 and 21 (each cycle was 28 days)
Phase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 12 Hours Post-Dose (AUC0-12) of Tazemetostat
Blood samples were collected at specified timepoints for the assessment of AUC0-12 of tazemetostat.
Time frame: Up to 12 hours post-dose on Cycle 1 Days 2 and 21 (each cycle was 28 days)
Phase 1b: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 24 Hours Post-Dose (AUC0-24) of Enzalutamide
Blood samples were collected at specified timepoints for the assessment of AUC0-24 of enzalutamide.
Time frame: Up to 24 hours post-dose on Cycle 1 Days 1, 2 and 21 (each cycle was 28 days)
Phase 2: Maximum Plasma Concentration of Enzalutamide
For Phase 2, PK blood samples for assessment of Cmax of enzalutamide were pre-specified to be collected at different time points by treatment arm. In the Phase 2: Tazemetostat 1200 mg + Enzalutamide arm, samples were collected at Cycle 1 Days 2 and 21 only. In the Phase 2: Enzalutamide arm, samples were collected at Cycle 1 Day 1 only. No PK samples were collected at other time points for these arms.
Time frame: Cycle 1 Days 2 and 21 for Phase 2: Tazemetostat 1200 mg + Enzalutamide arm and Cycle 1 Day 1 for Phase 2: Enzalutamide arm (each cycle was 28 days)
Phase 2: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Enzalutamide
For Phase 2, PK blood samples for assessment of AUC0-last of enzalutamide were pre-specified to be collected at different time points by treatment arm. In the Phase 2: Tazemetostat 1200 mg + Enzalutamide arm, samples were collected at Cycle 1 Days 2 and 21 only. In the Phase 2: Enzalutamide arm, samples were collected at Cycle 1 Day 1 only. No PK samples were collected at other time points for these arms.
Time frame: Cycle 1 Days 2 and 21 for Phase 2: Tazemetostat 1200 mg + Enzalutamide arm and Cycle 1 Day 1 for Phase 2: Enzalutamide arm (each cycle was 28 days)
Phase 2: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of 24 Hours Post-Dose of Enzalutamide
For Phase 2, PK blood samples for assessment of enzalutamide AUC0-24 were pre-specified to be collected at different time points by treatment arm. In the Phase 2: Tazemetostat 1200 mg + Enzalutamide arm, samples were collected at Cycle 1 Days 2 and 21 only. In the Phase 2: Enzalutamide arm, samples were collected at Cycle 1 Day 1 only. No PK samples were collected at other time points for these arms.
Time frame: Up to 24 hours post-dose on Cycle 1 Days 2 and 21 for Phase 2: Tazemetostat 1200 mg + Enzalutamide arm and up to 24 hours post-dose on Cycle 1 Day 1 for Phase 2: Enzalutamide arm (each cycle was 28 days)
Phase 2: Change From Baseline in Functional Assessment of Cancer Therapy-Prostrate (FACT-P): Functional Well-being Subscale (FWB) and Prostate Cancer Subscale (PCS) Scores
FACT-P questionnaire included subscales:physical well-being(PWB) (Questions \[Q\] GP1 to GP7),social/family well-being subscale(SWB) (Q GS1 to GS7),emotional well-being subscale(EWB) (Q GE1 to GE6),functional well-being subscale(FWB) (Q GF1 to GF7) and prostate cancer subscale(PCS) (Q C2, C6, P1 to P8, BL2 and BL5). Each question had 5 responses, 0: "not at all", 1: "a little bit", 2: "somewhat", 3: "quite a bit" and 4: "very much". Scores ranged from 0 ("not at all") to 4 ("very much") for positively phrased questions. Negatively phrased questions had a reverse scoring, from 0 ("very much") to 4 ("not at all"). Q that were reversed (via subtraction of the response from 4) were: GP1-7, GE1, GE3-6, C2, P1-3, P6-P8 and BL2. Total FACT-P score was sum of scores of all sub-scales (PWB, SWB, EWB, FWB and PCS). Higher scores: better quality of life. Baseline: last value recorded for a variable prior to or on date of randomization. Change from baseline in FWB and PCS scores is presented.
Time frame: Baseline (Day 1), Cycle (C) 3 Day 57, C 5 Day 113, C 7 Day 169, C 10 Day 253, C 13 Day 337, C 14 Day 421, C 15 Day 505, C 16 Day 589, C 17 Day 673, C 18 Day 757, C 19 Day 841, C 20 Day 925, C 21 Day 1009, C 22 Day 1093, C 23 Day 1177 and C 24 Day 1261
Phase 2: Time to Definitive Deterioration (TDD) in Prostate Symptoms as Assessed by the Functional Assessment of Cancer Therapy-Prostrate: Prostate Cancer Subscale Score
TTD was defined as the interval from date of randomization until date of first clinically meaningful deterioration (3 points or more decline for subscale score, 10 points or more decline for total score) that was confirmed at subsequent visit at least 3 weeks apart with no improvement in between visits or death (by any cause) in absence of a clinically meaningful deterioration, regardless of whether participant discontinued study drug(s) prior to deterioration. PCS included Q C2, C6, P1 to P8, BL2 and BL5. Each question had 5 responses,0: "not at all",1: "a little bit",2: "somewhat",3: "quite a bit" and 4: "very much". Scores ranged from 0 ("not at all") to 4 ("very much") for positively phrased questions. Negatively phrased questions had a reverse scoring, from 0 ("very much") to 4 ("not at all"). Total FACT-P: sum of scores of all sub-scales(PWB, SWB, EWB, FWB and PCS). Higher scores: better quality of life. TDD in prostate symptoms as assessed by FACT-P: PCS score is presented.
Time frame: Baseline (Day 1) up to Cycle 24 Day 1261
This Phase 1b/2, 2-part, open-label study was conducted at 21 sites in asymptomatic or mildly symptomatic participants with progressive, metastatic castration resistant prostate cancer (mCRPC).
| Milestone | Phase 1b: Tazemetostat 400 mg + Enzalutamide | Phase 1b: Tazemetostat 600 mg + Enzalutamide | Phase 1b: Tazemetostat 800 mg + Enzalutamide | Phase 1b: Tazemetostat 1200 mg + Enzalutamide | Phase 1b: Tazemetostat 1600 mg + Enzalutamide | Phase 1b: Tazemetostat 400 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 600 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 3 | 3 | 3 | 3 | 1 | 3 | 3 | 41 | 40 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 2 | 3 | 3 | 3 | 3 | 1 | 3 | 3 | 41 | 40 |
| Withdrew: Progressive disease | 1 | 3 | 3 | 3 | 2 | 1 | 3 | 3 | 28 | 28 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 |
| Withdrew: Sponsor request | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Non- compliance with study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product and which did not necessarily had a causal relationship with this study drug. An SAE was an AE which occurred during any study phase and at any dose of study drug, that fulfilled 1 or more of following: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital abnormality or birth defect, or was an important medical event that might jeopardize the participant or might require medical intervention to prevent one of the outcomes listed above. TEAEs were AEs that started or worsened in severity on or after the date of the first dose of study drug through 30 after the end of study drug, or prior to initiation of another investigational agent or cytotoxic chemotherapy. The treatment-emergent non-serious AEs are presented with a frequency threshold of 5%.
| Participants | Phase 1b: Tazemetostat 400 mg + Enzalutamide | Phase 1b: Tazemetostat 600 mg + Enzalutamide | Phase 1b: Tazemetostat 800 mg + Enzalutamide | Phase 1b: Tazemetostat 1200 mg + Enzalutamide | Phase 1b: Tazemetostat 1600 mg + Enzalutamide | Phase 1b: Tazemetostat 400 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 600 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone |
|---|---|---|---|---|---|---|---|---|
| Treatment-emergent non-serious AEs | 2 | 3 | 3 | 3 | 3 | 1 | 3 | 3 |
| TESAEs | 0 | 1 | 0 | 0 | 2 | 0 | 1 | 1 |
RP2D was based on pharmacokinetics (PK) parameters, pharmacodynamics (PD) parameters as well as efficacy and the overall tolerability of each combination (tazemetost with enzalutamide or tazemetostat with abiraterone/prednisone).
| mg | Phase 1b: Tazemetostat Dose-escalation |
|---|---|
| Phase 1b: Recommended Phase 2 Dose (RP2D) of Tazemetostat | 1200 |
rPFS was defined as the time from date of randomization (phase 2)/date of first dose of study drug (phase 1b) to the first objective evidence of radiographic progression using response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) (soft tissue) and prostate cancer clinical trials working group 3 (PCWG3) (bone), or death from any cause, whichever occurred first. The radiographic PD for soft tissue lesion was determined based on computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria and no confirmatory scan was required for soft tissue PD; for bone lesion was determined by 2 or more new bone lesions on bone scan per PCWG3 criteria (i.e., the appearance of 2 or more new bone lesions on bone scan) and the 2 scans (i.e., the confirmatory scan is required for bone disease progression) should be at least 6 weeks apart from each other.
| months | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|
| Phase 2: Radiographic Progression-Free Survival (rPFS) | 22.1 (16.6 to 27.6) | 11.1 (5.7 to 16.5) |
Blood samples were collected for evaluation of PSA. Confirmed PSA50 response was defined as \>=50% decline of PSA from baseline at any time on study for participants with a baseline PSA \>=1.0 microgram per liter (mcg/L) (nanogram/milliliter \[ng/mL\]) per PCWG3 criteria. Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization.
| percentage of participants | Phase 1b: Tazemetostat + Enzalutamide | Phase 1b: Tazemetostat + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|---|---|
| Phase 1b and 2: Percentage of Participants With Confirmed Prostate-Specific Antigen >=50% (PSA50) Response | 28.6 (8.39 to 58.10) | 14.3 (0.36 to 57.87) | 19.5 (8.82 to 34.87) | 15.0 (5.71 to 29.84) |
ORR was defined as the percentage of participants with complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions, any pathological lymph nodes (LN) must be \<10 millimeter (mm) in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.
| percentage of participants | Phase 1b: Tazemetostat + Enzalutamide | Phase 1b: Tazemetostat + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|---|---|
| Phase 1b and 2: Objective Response Rate (ORR) | 16.7 (0.42 to 64.12) | 0.0 (0 to 97.50) | 10.0 (0.25 to 44.50) | 0.0 (0 to 23.16) |
BOR was defined as percentage of participants with CR, PR, stable disease (SD), PD, or not evaluable (NE). CR was defined as disappearance of all target lesions, any pathological LN must be \<10 mm in the short axis. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the drug started. In addition, the sum had an absolute increase from nadir of 5 mm. NE was defined as which cannot be classified by 1 of the above preceding definitions. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Phase 1b: Tazemetostat + Enzalutamide | Phase 1b: Tazemetostat + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|---|---|
| Complete response | 0.0 | 0.0 | 0.0 | 0.0 |
| Partial response | 16.7 | 0.0 | 10.0 | 0.0 |
| Stable disease | 66.7 | 100.0 | 70.0 | 57.1 |
| Progressive disease | 16.7 | 0.0 | 20.0 | 35.7 |
| Not evaluable | 0.0 | 0.0 | 0.0 | 7.1 |
DCR at 6 months (24 weeks) was defined as percentage of participants with measurable soft tissue disease at baseline who had BOR of CR or PR and remaining on study without progression at 23 weeks or with a duration of SD for at least 23 weeks after of randomization (phase 2)/first dose (phase 1b) using overall imaging-based response assessed by RECIST 1.1 (soft tissue) and PCWG-3 criteria (bone). BOR: percentage of participants with CR, PR, SD, PD, or NE. CR: disappearance of all target lesions, any pathological LN must be \<10 mm in the short axis. PR: at least a 30% decrease in sum of diameters of target lesions, taking as a reference, baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: at least a 20% increase in sum of diameters of target lesions, taking as a reference, smallest sum of diameters recorded since the drug started. In addition, sum had an absolute increase from nadir of 5 mm.
| percentage of participants | Phase 1b: Tazemetostat + Enzalutamide | Phase 1b: Tazemetostat + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|---|---|
| Phase 1b and 2: Disease Control Rate (DCR) at 6 Months | 50.0 (11.81 to 88.19) | 100.0 (2.50 to 100) | 40.0 (12.16 to 73.76) | 21.4 (4.66 to 50.80) |
Time to first SRE per PCWG3 criteria was defined as the time from the date of randomization (phase II)/date of the first dose of study drug (phase Ib) to the date of first SRE. An SRE was defined as radiation therapy or surgery to bone, pathologic bone fracture, or spinal cord compression.
| months | Phase 1b: Tazemetostat + Enzalutamide | Phase 1b: Tazemetostat + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|---|---|
| Phase 1b and 2: Time to First Skeletal-Related Event (SRE) Per Prostate Cancer Clinical Trials Working Group 3 Criteria | 16.2 (4.4 to NA) | 26.3 (4.0 to NA) | NA (16.9 to NA) | NA (9.0 to NA) |
TTNT was defined as the time from the date of randomization (phase II)/date of the first dose of the study drug (phase Ib) to the date of the first documented administration of systemic treatment for prostate cancer.
| months | Phase 1b: Tazemetostat + Enzalutamide | Phase 1b: Tazemetostat + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|---|---|
| Phase 1b and 2: Time to Initiation of the Next Systemic Treatment (TTNT) for Prostate Cancer | 8.2 (2.6 to 13.9) | 13.4 (5.4 to NA) | 9.0 (6.5 to 17.0) | 10.6 (5.0 to 15.9) |
TTPP was defined as the duration from the date of randomization (phase II)/date of first dose of study drug (phase Ib) to the date of first PSA progression per PCWG3 criteria. PSA progression was defined as a \>=25% increase and an absolute increase of \>=2 mcg/L (2 ng/mL) above the nadir (or baseline value for participants who did not have a decline in PSA value beyond 12 weeks). Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization.
| months | Phase 1b: Tazemetostat + Enzalutamide | Phase 1b: Tazemetostat + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|---|---|
| Phase 1b and 2: Time to Prostate-Specific Antigen Progression (TTPP) | 4.6 (2.1 to 8.3) | 2.8 (2.8 to 4.6) | 4.6 (3.3 to 11.1) | 3.0 (2.8 to 5.6) |
Blood samples were collected for evaluation of CTC. Reduction in CTC was defined as participants from a state of having a detectable number of CTCs to having an undetectable number of CTCs. Percentage of participants with detectable CTC at baseline and non-detectable CTC are presented. Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization. Percentage of participants with detectable CTC at baseline and non-detectable CTC at any post-baseline time point up to 149 weeks and 191 weeks for Phase 1b and Phase 2 respectively are presented.
| percentage of participants | Phase 1b: Tazemetostat + Enzalutamide | Phase 1b: Tazemetostat + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|---|---|
| Detectable CTC at baseline | 64.3 | 100.0 | 36.6 | 52.5 |
| Non-detectable CTC | 35.7 | 0.0 | 63.4 | 47.5 |
Blood samples were collected for evaluation of CTC. CTC response was defined as a \>=30% reduction in CTC number from baseline in participants who entered the study. Baseline was defined as: Phase 1b: last value recorded for a variable prior to or on the date the participant received the first dose of study drug; Phase 2: last value recorded for a variable prior to or on the date of randomization.
| percentage of participants | Phase 1b: Tazemetostat + Enzalutamide | Phase 1b: Tazemetostat + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|---|---|
| Phase 1b and 2: Percentage of Participants With Circulating Tumor Cells Response | 88.9 (51.75 to 99.72) | 100.0 (59.04 to 100.00) | 80.0 (51.91 to 95.67) | 42.9 (21.82 to 65.98) |
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product and which did not necessarily had a causal relationship with this study drug. An SAE was an AE which occurred during any study phase and at any dose of the study drug, that fulfilled 1 or more of following: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital abnormality or birth defect, or was an important medical event that might jeopardize the participant or might require medical intervention to prevent one of the outcomes listed above. TEAEs were AEs that started or worsened in severity on or after the date of the first dose of study drug through 30 after end of study drug, or prior to initiation of another investigational agent or cytotoxic chemotherapy. The treatment-emergent non-serious AEs are presented with a frequency threshold of 5%.
| Participants | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|
| Treatment-emergent non-serious AEs | 41 | 39 |
| TESAEs | 13 | 10 |
Blood samples were collected at specified timepoints for the assessment of AUC0-last of tazemetostat.
| hour*nanograms per milliliter (ng/mL) | Phase 1b: Tazemetostat 400 mg + Enzalutamide | Phase 1b: Tazemetostat 600 mg + Enzalutamide | Phase 1b: Tazemetostat 800 mg + Enzalutamide | Phase 1b: Tazemetostat 1200 mg + Enzalutamide | Phase 1b: Tazemetostat 1600 mg + Enzalutamide | Phase 1b: Tazemetostat 400 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 600 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 2 | 1640 ± 150 | 3350 ± 2020 | 2860 ± 866 | 7060 ± 1580 | 6830 ± 5880 | NA ± NA | 3480 ± 2990 | 4380 ± 4680 |
| Cycle 1 Day 21 | NA ± NA | 1230 ± 168 | 1490 ± 606 | 2800 ± 2020 | 1120 ± 620 | NA ± NA | 2290 ± 1100 | 3500 ± 1570 |
Blood samples were collected at specified timepoints for the assessment of Cmax of tazemetostat.
| ng/mL | Phase 1b: Tazemetostat 400 mg + Enzalutamide | Phase 1b: Tazemetostat 600 mg + Enzalutamide | Phase 1b: Tazemetostat 800 mg + Enzalutamide | Phase 1b: Tazemetostat 1200 mg + Enzalutamide | Phase 1b: Tazemetostat 1600 mg + Enzalutamide | Phase 1b: Tazemetostat 400 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 600 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 2 | 341 ± 69.3 | 911 ± 609 | 888 ± 97.8 | 1470 ± 217 | 1730 ± 1100 | NA ± NA | 851 ± 348 | 1060 ± 916 |
| Cycle 1 Day 21 | NA ± NA | 364 ± 36.8 | 530 ± 436 | 568 ± 341 | 254 ± 118 | NA ± NA | 810 ± 327 | 1140 ± 646 |
Blood samples were collected at specified timepoints for the assessment of AUC0-8 of tazemetostat.
| hour*ng/mL | Phase 1b: Tazemetostat 400 mg + Enzalutamide | Phase 1b: Tazemetostat 600 mg + Enzalutamide | Phase 1b: Tazemetostat 800 mg + Enzalutamide | Phase 1b: Tazemetostat 1200 mg + Enzalutamide | Phase 1b: Tazemetostat 1600 mg + Enzalutamide | Phase 1b: Tazemetostat 400 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 600 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 2 | 1240 ± 705 | 3350 ± 2020 | 2860 ± 866 | 7060 ± 1580 | 6830 ± 5880 | NA ± NA | 3130 ± 2390 | 4380 ± 4680 |
| Cycle 1 Day 21 | NA ± NA | 1230 ± 168 | 1490 ± 606 | 3770 ± 1590 | 1440 ± 310 | NA ± NA | 2280 ± 1560 | 3500 ± 1570 |
Blood samples were collected at specified timepoints for the assessment of AUC0-12 of tazemetostat.
| hour*ng/mL | Phase 1b: Tazemetostat 400 mg + Enzalutamide | Phase 1b: Tazemetostat 600 mg + Enzalutamide | Phase 1b: Tazemetostat 800 mg + Enzalutamide | Phase 1b: Tazemetostat 1200 mg + Enzalutamide | Phase 1b: Tazemetostat 1600 mg + Enzalutamide | Phase 1b: Tazemetostat 400 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 600 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 2 | NA ± NA | — | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 4480 ± 3460 | NA ± NA |
| Cycle 1 Day 21 | — | 1300 ± 121 | 1800 ± 863 | — | — | NA ± NA | NA ± NA | — |
Blood samples were collected at specified timepoints for the assessment of AUC0-24 of enzalutamide.
| hour*ng/mL | Phase 1b: Tazemetostat 400 mg + Enzalutamide | Phase 1b: Tazemetostat 600 mg + Enzalutamide | Phase 1b: Tazemetostat 800 mg + Enzalutamide | Phase 1b: Tazemetostat 1200 mg + Enzalutamide | Phase 1b: Tazemetostat 1600 mg + Enzalutamide |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | NA ± NA | 33000 ± 15600 | 28800 ± 5780 | 36800 ± 6440 | 27500 ± 5270 |
| Cycle 1 Day 2 | 56700 ± 7900 | 57700 ± 30100 | 57400 ± 18400 | 66800 ± 10500 | 60300 ± 19900 |
| Cycle 1 Day 21 | NA ± NA | 272000 ± 106000 | 263000 ± 50400 | 251000 ± 47400 | 199000 ± 30800 |
For Phase 2, PK blood samples for assessment of Cmax of enzalutamide were pre-specified to be collected at different time points by treatment arm. In the Phase 2: Tazemetostat 1200 mg + Enzalutamide arm, samples were collected at Cycle 1 Days 2 and 21 only. In the Phase 2: Enzalutamide arm, samples were collected at Cycle 1 Day 1 only. No PK samples were collected at other time points for these arms.
| ng/mL | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|
| Cycle 1 Day 1 | — | 3000 ± 577 |
| Cycle 1 Day 2 | 3960 ± 773 | — |
| Cycle 1 Day 21 | 12100 ± 3080 | — |
For Phase 2, PK blood samples for assessment of AUC0-last of enzalutamide were pre-specified to be collected at different time points by treatment arm. In the Phase 2: Tazemetostat 1200 mg + Enzalutamide arm, samples were collected at Cycle 1 Days 2 and 21 only. In the Phase 2: Enzalutamide arm, samples were collected at Cycle 1 Day 1 only. No PK samples were collected at other time points for these arms.
| hour*ng/mL | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|
| Cycle 1 Day 1 | — | 30100 ± 9540 |
| Cycle 1 Day 2 | 60400 ± 17200 | — |
| Cycle 1 Day 21 | 259000 ± 67300 | — |
For Phase 2, PK blood samples for assessment of enzalutamide AUC0-24 were pre-specified to be collected at different time points by treatment arm. In the Phase 2: Tazemetostat 1200 mg + Enzalutamide arm, samples were collected at Cycle 1 Days 2 and 21 only. In the Phase 2: Enzalutamide arm, samples were collected at Cycle 1 Day 1 only. No PK samples were collected at other time points for these arms.
| hour*ng/mL | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|
| Cycle 1 Day 1 | — | 31400 ± 8430 |
| Cycle 1 Day 2 | 60000 ± 17000 | — |
| Cycle 1 Day 21 | 253000 ± 64500 | — |
FACT-P questionnaire included subscales:physical well-being(PWB) (Questions \[Q\] GP1 to GP7),social/family well-being subscale(SWB) (Q GS1 to GS7),emotional well-being subscale(EWB) (Q GE1 to GE6),functional well-being subscale(FWB) (Q GF1 to GF7) and prostate cancer subscale(PCS) (Q C2, C6, P1 to P8, BL2 and BL5). Each question had 5 responses, 0: "not at all", 1: "a little bit", 2: "somewhat", 3: "quite a bit" and 4: "very much". Scores ranged from 0 ("not at all") to 4 ("very much") for positively phrased questions. Negatively phrased questions had a reverse scoring, from 0 ("very much") to 4 ("not at all"). Q that were reversed (via subtraction of the response from 4) were: GP1-7, GE1, GE3-6, C2, P1-3, P6-P8 and BL2. Total FACT-P score was sum of scores of all sub-scales (PWB, SWB, EWB, FWB and PCS). Higher scores: better quality of life. Baseline: last value recorded for a variable prior to or on date of randomization. Change from baseline in FWB and PCS scores is presented.
| score on a scale | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|
| FWB: Cycle 3 Day 57 | -0.8 ± 4.73 | -1.2 ± 6.22 |
| FWB: Cycle 5 Day 113 | -0.8 ± 4.61 | -0.6 ± 4.14 |
| FWB: Cycle 7 Day 169 | -0.1 ± 5.68 | 1.4 ± 5.72 |
| FWB: Cycle 10 Day 253 | -0.6 ± 4.82 | -0.6 ± 5.11 |
| FWB: Cycle 13 Day 337 | 0.4 ± 3.58 | 1.1 ± 4.61 |
| FWB: Cycle 14 Day 421 | 2.1 ± 4.32 | 1.0 ± 6.44 |
| FWB: Cycle 15 Day 505 | 0.3 ± 2.70 | 1.7 ± 5.09 |
| FWB: Cycle 16 Day 589 | 0.4 ± 3.46 | 5.0 ± 6.06 |
| FWB: Cycle 17 Day 673 | 1.4 ± 3.50 | 2.0 ± 4.64 |
| FWB: Cycle 18 Day 757 | 1.7 ± 1.51 | 5.0 ± 4.36 |
| FWB: Cycle 19 Day 841 | 2.6 ± 3.51 | 7.5 ± 3.54 |
| FWB: Cycle 20 Day 925 | 2.0 ± 4.00 | 4.0 ± 4.24 |
| FWB: Cycle 21 Day 1009 | 1.7 ± 2.31 | — |
| FWB: Cycle 22 Day 1093 | 2.7 ± 4.73 | — |
| FWB: Cycle 23 Day 1177 | 4.5 ± 6.36 | — |
| FWB: Cycle 24 Day 1261 | 7.0 | — |
| PCS: Cycle 3 Day 57 | -0.8 ± 5.69 | -1.3 ± 5.85 |
| PCS: Cycle 5 Day 113 | -0.9 ± 5.12 | -0.7 ± 4.60 |
| PCS: Cycle 7 Day 169 | -1.2 ± 6.07 | -0.8 ± 5.08 |
| PCS: Cycle 10 Day 253 | 0.0 ± 7.62 | -0.4 ± 7.89 |
| PCS: Cycle 13 Day 337 | 0.8 ± 5.63 | -1.8 ± 7.73 |
| PCS: Cycle 14 Day 421 | 0.8 ± 6.82 | -0.8 ± 5.19 |
| PCS: Cycle 15 Day 505 | 2.0 ± 5.02 | 4.1 ± 2.65 |
| PCS: Cycle 16 Day 589 | 2.3 ± 3.49 | 2.6 ± 6.26 |
| PCS: Cycle 17 Day 673 | 1.6 ± 5.50 | 3.6 ± 3.07 |
| PCS: Cycle 18 Day 757 | 1.3 ± 3.72 | 0.2 ± 6.81 |
| PCS: Cycle 19 Day 841 | 1.8 ± 3.50 | 7.3 ± 1.80 |
| PCS: Cycle 20 Day 925 | 3.3 ± 4.73 | -1.0 ± 7.07 |
| PCS: Cycle 21 Day 1009 | 5.0 ± 1.73 | — |
| PCS: Cycle 22 Day 1093 | 6.0 ± 2.65 | — |
| PCS: Cycle 23 Day 1177 | 6.5 ± 0.71 | — |
| PCS: Cycle 24 Day 1261 | 3.0 | — |
TTD was defined as the interval from date of randomization until date of first clinically meaningful deterioration (3 points or more decline for subscale score, 10 points or more decline for total score) that was confirmed at subsequent visit at least 3 weeks apart with no improvement in between visits or death (by any cause) in absence of a clinically meaningful deterioration, regardless of whether participant discontinued study drug(s) prior to deterioration. PCS included Q C2, C6, P1 to P8, BL2 and BL5. Each question had 5 responses,0: "not at all",1: "a little bit",2: "somewhat",3: "quite a bit" and 4: "very much". Scores ranged from 0 ("not at all") to 4 ("very much") for positively phrased questions. Negatively phrased questions had a reverse scoring, from 0 ("very much") to 4 ("not at all"). Total FACT-P: sum of scores of all sub-scales(PWB, SWB, EWB, FWB and PCS). Higher scores: better quality of life. TDD in prostate symptoms as assessed by FACT-P: PCS score is presented.
| months | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|
| Phase 2: Time to Definitive Deterioration (TDD) in Prostate Symptoms as Assessed by the Functional Assessment of Cancer Therapy-Prostrate: Prostate Cancer Subscale Score | 11.2 (3.9 to NA) | 3.7 (2.5 to 11.1) |
Collected over TEAEs were collected from first dose of study drug (Day 1) up to either 30 days after last dose of study drug or until initiation of subsequent anticancer therapy or end of treatment visit. Assessed up to 149 weeks and 191 weeks for Phase 1b and Phase 2 respectively. All-cause mortality (deaths) were collected from first dose of study drug (Day 1) to the end of follow-up for death for each participant, up to approximately 259 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b: Tazemetostat 400 mg + Enzalutamide | 2/2 (100%) | 0/2 (0%) | 2/2 (100%) |
| Phase 1b: Tazemetostat 600 mg + Enzalutamide | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1b: Tazemetostat 800 mg + Enzalutamide | 2/3 (66.7%) | 0/3 (0%) | 3/3 (100%) |
| Phase 1b: Tazemetostat 1200 mg + Enzalutamide | 3/3 (100%) | 0/3 (0%) | 3/3 (100%) |
| Phase 1b: Tazemetostat 1600 mg + Enzalutamide | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase 1b: Tazemetostat 400 mg + Abiraterone/Prednisone | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Phase 1b: Tazemetostat 600 mg + Abiraterone/Prednisone | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 2: Tazemetostat 1200 mg + Enzalutamide | 7/41 (17.1%) | 13/41 (31.7%) | 41/41 (100%) |
| Phase 2: Enzalutamide | 18/40 (45%) | 10/40 (25%) | 39/40 (97.5%) |
| Event | Phase 1b: Tazemetostat 400 mg + Enzalutamide | Phase 1b: Tazemetostat 600 mg + Enzalutamide | Phase 1b: Tazemetostat 800 mg + Enzalutamide | Phase 1b: Tazemetostat 1200 mg + Enzalutamide | Phase 1b: Tazemetostat 1600 mg + Enzalutamide | Phase 1b: Tazemetostat 400 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 600 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|---|---|---|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/2 | 0/3 | 0/3 | 0/3 | 1/3 | 0/1 | 0/3 | 0/3 | 1/41 | 2/40 |
| PneumoniaInfections and infestations | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 0/1 | 1/3 | 0/3 | 1/41 | 1/40 |
| Urinary tract infectionInfections and infestations | 0/2 | 1/3 | 0/3 | 0/3 | 0/3 | 0/1 | 0/3 | 0/3 | 0/41 | 1/40 |
| ConstipationGastrointestinal disorders | 0/2 | 0/3 | 0/3 | 0/3 | 1/3 | 0/1 | 0/3 | 0/3 | 0/41 | 0/40 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 0/1 | 0/3 | 1/3 | 0/41 | 0/40 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/2 | 0/3 | 0/3 | 0/3 | 1/3 | 0/1 | 0/3 | 0/3 | 0/41 | 0/40 |
| HydronephrosisRenal and urinary disorders | 0/2 | 1/3 | 0/3 | 0/3 | 0/3 | 0/1 | 0/3 | 0/3 | 0/41 | 0/40 |
| Back painMusculoskeletal and connective tissue disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 0/1 | 0/3 | 0/3 | 0/41 | 2/40 |
| Bone painMusculoskeletal and connective tissue disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 0/1 | 0/3 | 0/3 | 0/41 | 1/40 |
| Spinal cord compressionNervous system disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 0/1 | 0/3 | 0/3 | 1/41 | 1/40 |
| Event | Phase 1b: Tazemetostat 400 mg + Enzalutamide | Phase 1b: Tazemetostat 600 mg + Enzalutamide | Phase 1b: Tazemetostat 800 mg + Enzalutamide | Phase 1b: Tazemetostat 1200 mg + Enzalutamide | Phase 1b: Tazemetostat 1600 mg + Enzalutamide | Phase 1b: Tazemetostat 400 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 600 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide |
|---|---|---|---|---|---|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 0/2 | 2/3 | 0/3 | 0/3 | 1/3 | 1/1 | 0/3 | 1/3 | 3/41 | 8/40 |
| FatigueGeneral disorders | 0/2 | 3/3 | 1/3 | 2/3 | 1/3 | 1/1 | 2/3 | 0/3 | 26/41 | 12/40 |
| ConstipationGastrointestinal disorders | 0/2 | 1/3 | 1/3 | 1/3 | 0/3 | 1/1 | 1/3 | 0/3 | 7/41 | 6/40 |
| DiarrhoeaGastrointestinal disorders | 0/2 | 0/3 | 0/3 | 2/3 | 2/3 | 1/1 | 0/3 | 0/3 | 15/41 | 8/40 |
| DiverticulumGastrointestinal disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 1/1 | 0/3 | 0/3 | 0/41 | 0/40 |
| DizzinessNervous system disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 1/1 | 1/3 | 0/3 | 6/41 | 3/40 |
| Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 1/1 | 0/3 | 1/3 | 0/41 | 0/40 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 0/2 | 1/3 | 0/3 | 0/3 | 0/3 | 1/1 | 0/3 | 0/3 | 0/41 | 0/40 |
| TachypnoeaRespiratory, thoracic and mediastinal disorders | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 1/1 | 0/3 | 1/3 | 0/41 | 0/40 |
| Urinary tract infection fungalInfections and infestations | 0/2 | 0/3 | 0/3 | 0/3 | 0/3 | 1/1 | 0/3 | 0/3 | 0/41 | 0/40 |
Phase 1b: The safety population included all participants who received any dose of the study drugs. Phase 2: The intent-to-treat (ITT) population included all participants who were randomized into the study.
| Age, Customized(Participants) | Phase 1b: Tazemetostat 400 mg + Enzalutamide | Phase 1b: Tazemetostat 600 mg + Enzalutamide | Phase 1b: Tazemetostat 800 mg + Enzalutamide | Phase 1b: Tazemetostat 1200 mg + Enzalutamide | Phase 1b: Tazemetostat 1600 mg + Enzalutamide | Phase 1b: Tazemetostat 400 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 600 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| <65 years | 0 | 1 | 2 | 0 | 2 | 0 | 1 | 0 | 12 | 11 | 29 |
| >=65 years | 2 | 2 | 1 | 3 | 1 | 1 | 2 | 3 | 29 | 29 | 73 |
| Sex: Female, Male(Participants) | Phase 1b: Tazemetostat 400 mg + Enzalutamide | Phase 1b: Tazemetostat 600 mg + Enzalutamide | Phase 1b: Tazemetostat 800 mg + Enzalutamide | Phase 1b: Tazemetostat 1200 mg + Enzalutamide | Phase 1b: Tazemetostat 1600 mg + Enzalutamide | Phase 1b: Tazemetostat 400 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 600 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 2 | 3 | 3 | 3 | 3 | 1 | 3 | 3 | 41 | 40 | 102 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1b: Tazemetostat 400 mg + Enzalutamide | Phase 1b: Tazemetostat 600 mg + Enzalutamide | Phase 1b: Tazemetostat 800 mg + Enzalutamide | Phase 1b: Tazemetostat 1200 mg + Enzalutamide | Phase 1b: Tazemetostat 1600 mg + Enzalutamide | Phase 1b: Tazemetostat 400 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 600 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 5 | 3 | 12 |
| Not Hispanic or Latino | 2 | 2 | 3 | 2 | 2 | 0 | 3 | 2 | 35 | 33 | 84 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 4 | 6 |
| Race (NIH/OMB)(Participants) | Phase 1b: Tazemetostat 400 mg + Enzalutamide | Phase 1b: Tazemetostat 600 mg + Enzalutamide | Phase 1b: Tazemetostat 800 mg + Enzalutamide | Phase 1b: Tazemetostat 1200 mg + Enzalutamide | Phase 1b: Tazemetostat 1600 mg + Enzalutamide | Phase 1b: Tazemetostat 400 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 600 mg + Abiraterone/Prednisone | Phase 1b: Tazemetostat 800 mg + Abiraterone/Prednisone | Phase 2: Tazemetostat 1200 mg + Enzalutamide | Phase 2: Enzalutamide | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 7 |
| White | 2 | 3 | 2 | 3 | 3 | 1 | 3 | 3 | 35 | 31 | 86 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 3 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Data sharing details ↗ · www.ipsen.com
Ran from Nov 2019 to primary completion in Nov 2024, 59 months.
Results were first posted in Mar 2026, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tazemetostat · Enzalutamide